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Structure–activity relationshipHost defense antimicrobial peptides are key components of human innate immunity that plays an indispensible
role in human health.While there are multiple copies of cathelicidin genes in horses, cattle, pigs, and sheep, only
one cathelicidin gene is found in humans. Interestingly, this single cathelicidin gene can be processed into differ-
ent forms of antimicrobial peptides. LL-37, the most commonly studied form, is not only antimicrobial but also
possesses other functional roles such as chemotaxis, apoptosis, wound healing, immunemodulation, and cancer
metastasis. This article reviews recent advances made in structural and biophysical studies of human LL-37 and
its fragments, which serve as a basis to understand their antibacterial, anti-bioﬁlm and antiviral activities. High-
quality structures were made possible by using improved 2D NMRmethods for peptide fragments and 3D NMR
spectroscopy for intact LL-37. The two hydrophobic domains in the long amphipathic helix (residues 2–31) of LL-
37 separated by a hydrophilic residue serine 9 explain its cooperative binding to bacterial lipopolysaccharides
(LPS). Both aromatic rings (F5, F6, F17, and F27) and interfacial basic amino acids of LL-37 directly interact
with anionic phosphatidylglycerols (PG). Although the peptide sequences reported in the literature vary slightly,
there is a consensus that the central helix of LL-37 is essential for disrupting superbugs (e.g., MRSA), bacterial
bioﬁlms, and viruses such as human immunodeﬁciency virus 1 (HIV-1) and respiratory syncytial virus (RSV).
In the central helix, the central arginine R23 is of particular importance in binding to bacterial membranes or
DNA.Mapping the functional roles of the cationic amino acids of themajor antimicrobial region of LL-37 provides
a basis for designing antimicrobial peptideswith desired properties. This article is part of a Special Issue entitled:
Interfacially Active Peptides and Proteins. Guest Editors: William C. Wimley and Kalina Hristova.
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tides. In human sweat, LL-37 can be processed into shorter peptides such as KR-20, LL-23,
and KS-30 [35]. It is unclear whether ALL-38 can be processed in a similar manner in the
human reproductive system [34].1. Introduction
Antimicrobial peptides are host defense molecules of the innate
immunity of all life forms and have remained potent for millions of
years [1–4]. Interest in antimicrobial peptides has been on the rise
since the discoveries of cecropins from silk moths by Hans Boman,
magainins from African frogs by Michael Zasloff, and α-defensins
from human blood by Robert Lehrer in the 1980s [5–7]. According
to the antimicrobial peptide database (APD), over 2000 such pep-
tides have been characterized from a variety of biological sources,
ranging from bacteria, protozoa, fungi, and plants, to animals [8,9].
Antimicrobial peptides collected in the APD (http://aps.unmc.edu/AP)
are usually small (on average 32 amino acids), cationic (average net
charge +3.2) and contain on average 40% hydrophobic amino acids.
Such sequences are ideal for recognizing and neutralizing anionic
microbes. Therefore, there is a strong desire to develop antimicrobial
peptides into a new generation of therapies to meet the growing an-
tibiotic resistance problem.
One of the best studied antimicrobial peptides is human cathelicidin
LL-37, a 37-residue cationic peptide starting with a pair of leucines
[10–15]. Although the ﬁrst cathelicidin was identiﬁed in 1988 [16],
a cathelicidin-related therapeutic practice could be traced to over
100 years ago. Niels Finsen won Nobel Prize in 1903 for his light
therapy to treat tuberculosis. This therapy is now linked to LL-37.
Light can induce the synthesis of dihydroxylated form of vitamin D,
which binds to the receptor to induce the expression of human
cathelicidin gene [17,18]. The processed antimicrobial peptide LL-37
might have been responsible for the pathogen killing. Modern scientiﬁc
results further underscore the signiﬁcance of antimicrobial peptides to
human health. The lack of human LL-37 can cause the disease ofmorbus
Kostmann [19]. In acute and chronic lesions from patients with atopic
dermatitis, the expression of LL-37 as well as human beta defensin 2
(hBD-2) is suppressed [20]. In vitro antimicrobial assays demonstrated
antimicrobial activity of LL-37 against various pathogenic microbes,
including superbugs, HIV-1, inﬂuenza virus A, fungi, and parasites
[21–27]. LL-37 may be an important cancer marker and its fragments
may be developed into new anticancer agents [28]. These facts
explain the increased literature related to human cathelicidin LL-37
[29].
Human hCAP-18/LL-37 was ﬁrst discovered in 1995 by three lab-
oratories [30–32]. In this article, hCAP-18 represents the precursor
protein (i.e., human cationic protein of 18 kDa), while human
cathelicidin is reserved for the mature peptide (e.g. LL-37) that ex-
erts the antimicrobial action. The mature cathelicidin antimicrobial
peptides from different biological sources vary in amino acid, activi-
ty, and 3D structure. However, the precursor proteins share a highly
conserved “cathelin” domain. Cathelicidins have been found not only
in mammals but also in birds, amphibians, and ﬁsh. While many an-
imals contain multiple genes encoding different cathelicidins,
humans, rats, and mice have only one cathelicidin gene [10]. The sin-
gle human cathelicidin gene, however, can generate different forms
of cathelicidin peptides (Fig. 1A). In neutrophils, the precursor pro-
tein hCAP-18 is cleaved by proteinase to release LL-37 [33]. In the
human reproductive system, hCAP-18 in the sperm is processed
into ALL-38 within the vagina by gastricsin [34]. Compared to LL-
37, ALL-38 contains one additional alanine at the N-terminus.
These two forms of peptides have comparable antimicrobial activi-
ties. In human skin, other proteases can process human cathelicidin
into smaller fragments, whichmay or may not have antimicrobial ac-
tivity [35]. The various fragments of LL-37 further expand the human
defense arsenal. In addition to antimicrobial activity, human LL-37possesses many other functions such as chemotaxis, immune modu-
lation, and wound healing (Fig. 1B) [10–15].
This reviewdiscusses the advances in structural determination of LL-
37 and its important fragments. The high-quality structures of LL-37 and
its fragments set the stage for us to explainwhy certain LL-37 fragments
have stronger antimicrobial activities than others. In particular, the cen-
tral portion of LL-37 is now recognized as the key antibacterial, anti-
bioﬁlm and antiviral region. Remarkably, this portion corresponds to
the central helix in the 3D structure of LL-37 determined by 3D NMR
spectroscopy. Our systematic studies of the impact of alanine scanning
of cationic amino acids of the major antimicrobial region of LL-37 on
membrane permeation, disruption, and lipid clustering provide insight
into its mechanism of action.
2. NMR studies of human LL-37 yielded atomic pictures for
understanding its interactions with bacterial membranes
2.1. Bacterial membranes and membrane models for structural studies by
NMR
Biological membranes are complex and may contain multiple
layers with various molecules such as membrane proteins, carbohy-
drates, and lipids [36–38]. The membranes of different bacteria also
differ. The membrane compositions for a select set of bacteria are
listed in Table 1. A cartoon view of the surface of Gram-positive and
Gram-negative bacteria is given in Fig. 2. While Gram-positive bacteria
possess a cell wall outside the membrane, Gram-negative bacteria con-
tain an outer membrane. Furthermore, even Gram-negative bacteria
can have different membrane compositions (Table 1). In addition,
some resistant bacterial strains have developed mechanisms to modify
their membrane surface properties in order to compromise the effect of
cationic antimicrobial peptides [39,40]. However, there are also
common features. For example, bacterial membranes are characterized
by a large negative potential due to the dominance of anionic lipids such
Table 1
Lipid compositions of selected bacteria [101].
Bacterial species CL (% total lipid) PG (% total lipid) PE (% total lipid)
Gram-negative bacteria
Escherichia coli 5 15 80
Escherichia cloacae 3 21 74
Yersinia kristensenii 20 20 60
Proteus mirabilis 5 10 80
Klebsiella pneumoniae 6 5 82
Pseudomonas aeruginosa 11 21 60
Gram-positive bacteria
Staphylococcus aureus 42 58 0
Streptococcus pneumonia 50 50 0
Bacillus cereus 17 40 43
Bacillus polymyxa 8 3 60
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tial constitutes themajor driving force for cationic peptides to recognize
the anionic bacterial surface.Fig. 2. A cartoon view of themembranes of (A) Gram-negative bacteria and (B) Gram-positive b
membrane rich in LPS and the inner membrane rich in anionic PG. Gram-positive bacteria haveWhile there are direct observations of peptide effects on bacteria
by selected biophysical techniques [43,44], many studies were per-
formed in membrane model systems. These include lipid bilayers,
bicelles, and micelles [45,46]. Lipid bilayers are useful to establish
peptide orientation by solid-state NMR spectroscopy. Bicelles are a
membrane model between lipid bilayers and micelles. They can be
used for both liquid and solid-state NMR studies depending on the
size. However, for solution NMR studies, smaller micelles are preferred
because rapid tumbling of such membrane-mimetic systems leads to
high-resolution NMR spectra required for structural determination
[47]. Sodium dodecylsulfate (SDS) and dodecylphosphocholine (DPC)
are two commonly used micelles [45–50]. DPC has a lipid head group
identical to phospholipids predominantly found in human cells, where-
as SDS with an anionic head group mimics this aspect of bacterial
membranes.
Because the major anionic lipids in bacterial membranes are PG,
there is a desire to use a more relevant lipid. Based on a comparative
study of a series of short-chain phosphatidylglycerols, theWang labora-
tory selected dioctanoyl phosphatidylglycerol (D8PG) as a newbacterialacteria. Themembranes of Gram-negative bacteria are composed of two layers: the outer
a cell wall consisting of lipoteichoic acid and peptidoglycan and a cytoplasmic membrane.
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multiple advantages. First, it has the same lipid head group as the
major anionic lipid in bacterial membranes and should be biological-
ly more relevant than SDS. Second, it appears to be slightly larger
than the SDS micelle, making the surface less curved [56]. Third, a
better NMR spectral dispersion has been observed in D8PG than in
SDS for several peptides. The better spectral dispersion of the pep-
tides in D8PG may be ascribed to the lipid head group. For example,
the arginine side chain amide signals of LL-37 fragments are resolved
in D8PG but not in SDS or DPC [57], opening a useful window for de-
tection of peptide–lipid contact details via intermolecular NOESY ex-
periments [58]. Fourth, subtle differences in helix formation of
single-residue mutants are observed in D8PG but not in SDS [59].
As a consequence, D8PG is a unique bacterial membrane mimetic
model that enabled us to determine the 3D structure and membrane
surface location of an LL-37 peptide by using one sample and one ex-
periment [54].
2.2. Three-dimensional structure of human LL-37
Typical evidence for membrane targeting of LL-37 is that peptides
synthesized using all D-amino acids display similar antibacterial ac-
tivity to the native LL-37 consisting of L-amino acids [60]. This jus-
tiﬁes the structural determination in membranes. We chose anionic
SDS micelles as a bacterial membrane mimetic for NMR studies be-
cause the sample can be stable for a sufﬁcient time required to record
a variety of NMR spectra. The ﬁrst attempt to solve the 3D structure
of LL-37 in the Wang laboratory was made in 2004. It was found
that 2D 1H NMR did not offer enough spectral resolution for LL-37
in complex with SDSmicelles [61]. Further efforts were then devoted
to the expression and production of isotope-labeled peptides [62],
which enabled structural determination of LL-37 by 3D NMR spec-
troscopy [56]. In a 3D NMR spectrum [63], the NMR peaks initially
crowded on one 2D spectrum were separated onto several dozen
2D planes along the third 15N or 13C dimension. The power of this
3D NMR method can be analogously understood because a book
would become illegible had all the pages been printed onto a single
page! Therefore, every effort was taken to optimize spectral resolution.
The 3D structure of human LL-37 bound to SDS micelles is presented in
Fig. 3A. This LL-37 structure possesses a long amphipathic helix (resi-
dues 2–31) followed by a disordered tail (residues 32–37) [56]. In the
absence of peptide dynamic information, a ﬂexible polypeptide region
may be generated due to a limited number of NMR restraints or due
to peptide dynamics [64,65]. The order-disordered structural pattern
of LL-37 was validated by an independent measurement of the peptide
15N backbone dynamics, which indicates that residues 2–31 are indeed
rigid and only the C-terminal tail is mobile.
We should mention that the structure of LL-37 bound to DPC was
also determined by using the traditional 2D 1H NMR spectroscopy
[66]. A helix-break-helix motif between residues 4–34 was found with
both terminal residues ﬂexible. Such a structural pattern found in DPC
[66] differs from the ordered-disordered structural pattern determined
in SDS micelles [56]. Importantly, only the LL-37 structure (Fig. 3A) de-
termined in SDSmicelles can be applied to the LPS and PG-bound states
(below).
2.3. Structural basis of bacterial membrane binding of human LL-37
There is a strong desire to follow the action of antimicrobial peptides
on bacteria. Transmission electron microscopy (TEM) can be used to
view the effect of antimicrobial peptides on bacteria and some cell
envelope damages or disruption have been observed [59]. On the
other side of the coin, one can also follow the conformational states
of the peptide spectroscopically. Before the peptide reaches the bac-
teria, circular dichroism (CD) studies showed that LL-37 did not have
a deﬁned structure (i.e. random coiled state) and became helical atneutral pH or in complexwithmembranes [67]. Using NMR spectros-
copy, it is possible to precisely map the interactions of LL-37 with the
major components of the bacterial outer and inner membranes [56].
This was accomplished using an isotope-labeled LL-37 [62]. Consistent
with CD, the peptide is indeed disordered in water at pH 3.6. At pH 7,
the peptide forms a tetramer [67,68] involving residues 1–36 [68].
Lipopolysaccharides (LPS) are a major component of the Gram-
negative bacterial outer membrane (Fig. 2A). In complex with LPS, res-
idues 1–31 of LL-37 are involved in binding, but not the C-terminal tail
[56]. In the LL-37 structure, a hydrophilic S9 segregates the hydrophobic
surface of the long helix into two domains (Fig. 4A). This two-domain
structure explains the cooperative binding of LL-37 to LPS [69]. S9 ap-
pears to play a unique role in modulating peptide activity since a muta-
tion of S9 to either A9 or V9 reduces the antibacterial activity of LL-37
against E. coli [55].
The establishment of the D8PG model also enabled us to determine
the 3D structure of LL-37 bound to PG, which mimic the Gram-
negative bacterial inner membrane (Fig. 2A). All the NMR data indi-
cate that LL-37 bound to D8PG adopts the same structure as deter-
mined in SDS micelles [56]. It appears that the lipid head group or
number of lipid acyl chains did not affect the structure in the case
of LL-37. Hence, the ordered-disordered structure of LL-37 bound
to SDS can be extended to the cases of both LPS and PG-bound states.
This structure (Fig. 3A) forms the basis for understanding the inter-
actions of LL-37 with bacterial membranes.
2.4. Direct NMR evidence for peptide–membrane interactions
In many cases, if not all, NMR studies focus on either the peptide
portion (e.g. a full structural determination) or the membrane por-
tion [50]. While solution NMR was applied to determine the struc-
ture of frog antimicrobial and anticancer peptide aurein 1.2, solid-
state 31P NMR was used to probe lipid vesicle structures [70–74].
Likewise using solid-state NMR, a single amino acid labeled peptide
was used to determine the orientation of LL-37 on the lipid bilayer
[74], whereas the natural 31P probe was utilized to gauge lipid struc-
ture and motions [74,75]. However, a direct observation of the inter-
actions between antimicrobial peptides and membranes is rare. We
utilized solution NMR spectroscopy to provide direct evidence for
the binding of the long amphipathic helix of LL-37 (Fig. 3A) to mem-
branes [56]. Human LL-37 is a unique molecule with four aromatic
phenylalanines, which are outstanding probes for peptide binding
[51,54,70]. As an advantage of the use of protonated D8PG, we
were able to observe the direct dipole–dipole interactions between
the protons of peptide aromatic phenylalanines and the D8PG lipid.
The four aromatic rings (F5, F6, F17, and F27) of LL-37 are well posi-
tioned along the peptide chain (Fig. 4B green). Thus, both helical do-
mains in the long helix of the peptide are indeed involved in
membrane binding. In addition, the same intermolecular NOESY
spectrum of LL-37 in complex with D8PG also indicates direct inter-
actions of arginines with PG.
2.5. Structures of LL-37 fragments determined by the improved 2D NMR
method
Then, are all the arginines equally important or some more im-
portant than others? To facilitate our observation, we chose to use
the major antimicrobial region of human LL-37 [21]. This major anti-
microbial binding region was identiﬁed by NMR as illustrated in
Fig. 3. Initially, LL-37 was cut into two halves: LL-12 (i.e. residues
1–12) and IG-25 (i.e. residues 13–37). While LL-12 has a very short
helix at the N-terminus (Fig. 3B), a well-deﬁned helical structure
(residues 17–31) was observed in the central region of IG-25
bound to SDS (Fig. 3C) [61]. By trimming the C-terminal disordered
region of IG-25, we obtained a 20 residue peptide. In addition, we
swapped the positions between I13 and G14 since many natural
Fig. 3. Ribbon diagrams of the three-dimensional structures of human LL-37 and its fragments bound to membrane-mimetic micelles. (A) An ensemble of 5 structures of LL-37 is shown.
The structured region of LL-37 superimposeswell but not the disordered C-terminal tail. Also presented are NMR structures of LL-12 (B), IG-25 (C), GI-20 (D), GF-17 (E), and KR-12 (F). For
clarity, only the side chains of GF-17 and KR-12 are shown and labeled. The structures of LL-37 (PDB entry: 2K6O), LL-12 (PDB entry: 2FBU), IG-25 (PDB entry: 2FCG), and GF-17 (PDB
entry: 2L5M) were determined in the presence of SDS micelles [21,56,61], while the structures of GI-20 and KR-12 were determined in complex with D8PG [56,57]. In several cases in-
cluding LL-37 itself, we found a similar structure for the peptide in SDS and D8PG [56]. Note the conformational changes at the C-terminus of LL-12 (B) and at the N-terminus of IG-25
(C) compared to the conformation of intact LL-37 (A).
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20, is entirely helical (Fig. 3D) in complex with D8PG or DPC micelles
[54,57]. By trimming off both the disordered C-terminus and the less
structured N-terminus of IG-25, we obtained a 16-residue segment.
Again to better mimic natural antimicrobial peptides, a glycine was
inserted at the N-terminus. This peptide, GF-17, is referred to asthe major antimicrobial region of LL-37 [21]. GF-17 is entirely helical
in the presence of SDS micelles (Fig. 3E).
In the structures of both GF-17 and GI-20, including the smallest an-
tibacterial peptide KR-12 (Fig. 3F), R23 is located between the hydro-
phobic and hydrophilic interface (i.e., interfacial region). This location
can also be seen in the LL-37 structure, where only R23 is adjacent to
Fig. 4. The central helix stands out in the high-quality 3D structure of human LL-37 as the key antimicrobial region. (A)While the C-terminal tail does not participate inmembrane binding,
S9 splits the membrane-targeting hydrophobic surface (gold) of the long amphipathic helix (residues 2–31) into two domains: an N-terminal short helix and a long central helix. Such a
structure explains the cooperative binding of LL-37 to LPS [69]. It also indicates that the central helix is the key antimicrobial region of LL-37, which is responsible for antibacterial, anti-
bioﬁlm, and antiviral activities discussed in this article. (B) Identiﬁcation of important side chains of LL-37 directly involved inmembrane interactions by NMR. All of the four hydrophobic
aromatic rings of F5, F6, F17, and F27 (green), as well as cationic R23 (stick), interactwith phosphatidylglycerols. In this view, only the side chain of R23 is close to the hydrophobic surface
(gold). It is thus an important interfacial basic side chain required for membrane interactions or binding to other anionic components such as DNA.
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were detected by solution NMR only for R23, but not for R19 or R29 in
the NOESY spectra [54]. This R23 is essential for bacterial targeting be-
cause an alanine substitution reduced the antibacterial activity of GF-
17 against Gram-negative Escherichia coli [21]. This agreement between
biological and structural data underscored the importance of the inter-
facial arginine R23 (see also Fig. 4B).
In summary, our NMR structural studies led to (1) a high-quality 3D
structure for intact LL-37, which uses residues 2–31 to interact with
both LPS and PG [56]; (2) 3D structures for LL-12, KR-12, GF-17, GI-20,
IG-25 (Fig. 3) [21,57,61], and LL-23 [55]; and (3) successful observation
of direct interactions between arginines and PG as well as between aro-
matic phenylalanines and PG [54,56]. Structures of these LL-37 frag-
ments were determined by using improved 2D NMR methods. In this
improved method, additional NMR experiments are performed to en-
able the measurements of 13C and 15N chemical shifts at natural abun-
dance (i.e. without isotope labeling). Such heteronuclear chemical
shifts, not available in the traditional 2D proton NMR spectra recordedusing unlabeled peptides, are utilized for structural reﬁnement [70].
This method enables a more accurate deﬁnition of the structured re-
gions of the peptides, especially under the situations when the NOE re-
straints are insufﬁcient. The importance of this improved method has
been highlighted in a recent review article [64]. In certain cases, this
method can avoid the publication of misleading structure or dynamics.
Hence, these high-quality 3D structures and atomic details for
peptide–PG interactions laid a solid basis for us to discuss the struc-
ture–activity relationships of human LL-37 below.
3. Structural insight into antibacterial and antiviral activities of
LL-37 peptides
Since 1995, the antibacterial activities of human LL-37 have been eval-
uatedusingmultiple bacterial strains, including some resistant superbugs.
It is noticed that antibacterial activity data can vary for the same bacteri-
um. For example, LL-37 is active against Staphylococcus aureus ATCC
29213 [76], but is poorly active against methicillin-resistant S. aureus
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against MRSA at a low salt concentration [77]. It seems that assay proto-
cols, bacterial strains (including the mechanism of resistance), and assay
conditions (e.g. pH,media, salts, serum) allmatter in antimicrobial assays.
Because of these variables, the goal of this section is to review antimicro-
bial activity data of LL-37 and its related fragments obtained by the same
lab, using the same method, conditions and bacterial strains. Under such
conditions, we may attribute the activity difference to peptide sequences
and, whenever possible, explain peptide potency based on high-quality
3D structures of LL-37 and its fragments (Fig. 3).
3.1. Antibacterial and anti-bioﬁlm activities of LL-37 peptides
Johansson et al. ﬁrst compared LL-37 with N-terminally truncated
fragments [67]. LL-37 is active against E. coli D21 with a MIC of 5 μM.
In 5mMNa2SO4, LL-37 is more active than FF-33 and SK-29 (sequences
in Table 2). However, FF-33 is as potent as LL-37 in medium E. It seems
that the very N-terminal four residues LLGD are dispensable in medium
E. Subsequently, Shai and colleagues showed that LL-37 and FF-33 were
equally potent in permeating membranes. Interestingly, the LL-37
oligomers were maintained in vesicles with a phosphocholine head
group, but dissociated in PG-containing membranes, indicating that
LL-37 works as a monomer [78]. Hence, the monomeric 3D structure
of LL-37 determined in the presence of anionic D8PG or SDSwell rep-
resents the active form. In this structure (Fig. 4B), the aromatic rings
of F5 and F6 stack on each other as a result of aromatic–aromatic
interactions. We propose herein that this F5/F6 aromatic–aromatic
interaction may also play a role in LL-37 oligomerization, where a
group of aromatic rings can cluster. This requires at least two copies
of the LL-37molecule in a parallel position in the tetramer. This spec-
ulation explains why further removal of F5F6 from the LL-37 se-
quence reduced the propensity of SK-29 in forming oligomers. Braff
et al. found that N-terminal fragments such as RK-31 and KS-30
(Table 2) became more potent than LL-37 against Gram-positive,
Gram-negative bacteria and Candida albicans [79]. Ciornei et al. also
showed that removal of 2 or 6 residues from the N-terminal region
of LL-37 had little effect on peptide activity [80]. Others found that
both LL-31 and LL-32 exhibited a stronger killing effect than LL-37
[81,82]. All of these results suggest that the N-terminal short helix
of LL-37 (Fig. 4A) is less important for antibacterial activity.
Several studies pointed at the importance of the central region for
antimicrobial activity of LL-37. Sieprawska-Lupa et al. [83] identiﬁed
FK-21 (Table 2), a C-terminal fragment of LL-37 derived from a protease
degradation reaction. FK-21 displayed comparable minimal bactericidal
concentrations (MBC) to LL-37 in killing E. coli, B. subtilis, P. aeruginosa,
and E. faecalis. Nell et al. [84] scanned the LL-37 sequence with a win-
dow size of 22mer. Based on a comparison of a library of overlappingTable 2
Selected sequences of LL-37 and its fragments.
















LL-12 LLGDFFRKSKEK [61]LL-37 peptides, they identiﬁed IG-24 (Table 2), a central fragment of
LL-37, as the most promising segment in terms of antimicrobial and
anti-LPS activity. Using an in silico approach, Sigurdardottir et al. identi-
ﬁed a central fragment GKE-21 (Table 2), which is as potent as LL-37 in
killing bacteria [85]. Based on the NMR technology dubbed TOCSY-trim,
Wang was able to accurately map the major antimicrobial region of LL-
37 to residues 17–32 [61]. The same region is also implicated in the
structure of IG-25 when both ﬂexible tails are cleaved (Fig. 3C). A
resulting synthetic peptide GF-17 (Table 3) is highly potent against
both E. coli and community-associatedMRSAUSA300 LAC [21]. Interest-
ingly, this major antimicrobial segment (residues 17–32) discovered by
NMR is contained within FK-21, IG-24, or GKE-21, explaining the anti-
microbial potency of these fragments.
Also using a series of synthetic peptides, IG-19 (Table 2) was found
to be the shortest fragment of LL-37 that exhibited antibacterial activity
against Burkholderia thailandensis E264 [81]. The same peptide was also
identiﬁed as the best immunemodulatingpeptide in another study [86].
This IG-19 fragment is very similar to GI-20 (Table 3), which displays an
optimal therapeutic index against HIV-1 [22]. These observations make
sense, since GI-20, or a similar fragment IG-19, corresponds to the cen-
tral helix of LL-37 (Fig. 4A).
Antimicrobial activity assays are usually conducted using planktonic
bacteria cultivated under laboratory conditions (e.g., rich media,
240 rpm, and 37 °C). This does not necessarily reﬂect commensal con-
ditions or the microbial infectious states. In particular, bacteria fre-
quently exist in bioﬁlms, where many bacteria work together to
create a tower-like structure. Such a bacterial community is more
difﬁcult to eradicate. The loss of potency of many traditional antibiotics
demands more potent antimicrobials and antimicrobial peptides are
potential candidates [1–4]. Recently, Nagant et al. compared anti-
bioﬁlm activity of LL-37 with its fragments against P. aeruginosa PAO1
[87]. They found that the N-terminally or C-terminally truncated frag-
ments RK-31 and LL-31 (Table 2) were most potent. The central frag-
ment RK-25 (residues 7–31) displayed both strong antimicrobial and
anti-bioﬁlm activity. The authors proposed that this fragment is the
minimal sequence required for anti-bioﬁlm activity. Feng et al. [88]
evaluated antimicrobial and anti-bioﬁlm activities of LL-37 and frag-
ments against A. baumannii. The antimicrobial potency is in the
following order: KS-30 N LL-37 N KR-20 N KR-12. While all these
peptides can inhibit bioﬁlm formation, only KS-30 was able to dis-
rupt pre-formed bioﬁlms. It is evident that both RK-25 (Table 3)
and KS-30 (Table 2) peptides contain the central helix of LL-37
(Fig. 4A), explaining their anti-bioﬁlm potency.
3.2. Antiviral activities of LL-37
There is also high interest in identifying antiviral peptides. Some an-
timicrobial peptides are known to have antiviral effects. In the APD da-
tabase [8,9], 138 entries are annotated to possess antiviral activity as of
October 2013. Human LL-37, but not a scrambled sequence, is potent
against viruses [89]. For example, human cathelicidin could inhibit
orthopox virus (vaccinia) replication both in vitro and in vivo [90]. LL-
37 is potent against inﬂuenza virus A as well [89], probably by directly
disrupting the viral membranes rather than via viral aggregation [91].
Crack et al. found a reduced viral load of varicella zoster virus (VZV) in
infected keratinocytes and B cells due to the LL-37 expression [92].
In several cases, antiviral effects of both intact LL-37 and select
fragments were tested. LL-37 was shown to inhibit HIV-1 replication
in peripheral blood mononuclear cells (PBMC) [23,93]. Subsequently,
Wang et al. evaluated anti-HIV activity of a panel of LL-37 fragments,
and a central fragment, GI-20 (Table 3), showed the highest potency
as well as therapeutic index. F17, helicity, and sequence order of LL-37
peptides are all important for inhibiting HIV-1 replication [22], consis-
tent with its binding to the HIV-1 reverse transcriptase [94]. Currie
et al. [95] found that LL-37 is inhibitory to respiratory syncytial virus
(RSV) in vitro and early treatment (2 h after infection) is essential.
Table 3
Useful LL-37 templates for peptide design.
Peptide Amino acid sequence LL-37 region Activity Refs
KR-12 KRIVQRIKDFLR
(Minimal antibacterial region)
18–29 Anti-E. coli [56]
FK-13 FKRIVQRIKDFLR
(The LL-37 core peptide)
17–29 Minimal anti-HIV peptide [61]
GF-17 FKRIVQRIKDFLRNLV
(Major antimicrobial region, core)
17–32 Antibacterial (e.g.MRSA); anticancer [21,61]
GI-20 GIKEFKRIVQRIKDFLRNLV
(The central fragment)
13–32 Antiviral; immune modulationa [22,54,86]
RK-25 RKSKEKIGKEFKRIVQRIKDFLRNL 7–31 Anti-bioﬁlm [87]
a A similar sequence IG-19 was reported for immune modulation [86].
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residues 12–33 (KI-22, Table 2), while both the N-terminal (residues
1–22) and C-terminal fragments (residues 17–37) were ineffective.
These results all suggest the critical role of the central fragment in
inhibiting the infection of viruses such asHIV-1 and RSV (see the central
helix in Fig. 4A).
Antimicrobial peptides can usually work on viral envelopes. In
this case, the LL-37 structure determined in membranes (Fig. 3A)
can be useful to understand antiviral effects as well. However,
there are also cases where antimicrobial peptides interact with a
protein target. Human LL-37 appears to target HIV-1 reverse tran-
scriptase [94]. It seems that the central region of LL-37 is sufﬁcient
for the inhibition of most of the viruses mentioned above. This cen-
tral helix stands out in the 3D structure of LL-37—the N-terminal
helix is separated from the central helix by a hydrophilic serine at
position 9, while the very C-terminal tail is disordered and not re-
quired for membrane targeting (Fig. 4A). We propose that the helical
structure of this central peptide (corresponding to GI-20) could be
important for shutting down the viral machinery. This helical seg-
mentmay also be expected to promote positivemembrane curvature
that would inhibit viral fusion [96]. In particular, HIV-1 viral proteins
gp41 and gp120 can induce the formation of lipid rafts rich in choles-
terol and sphingolipids that facilitate the viral fusion with host mem-
branes. The interactions of LL-37 with such lipids could inhibit viral
fusion [97]. Indeed, fusion of a peptide with such lipids enhances an-
tiviral activity against enveloped viruses such as HIV-1 [98,99]. It
should be pointed out that certain antimicrobial peptides such as
human alpha-defensin HD-5 can directly neutralize non-enveloped
viruses, including human adenoviruses, papillomaviruses, and
polyomaviruses. For this action, select arginines and hydrophobic
residues of the peptide are essential [100]. Since the central fragment
of LL-37 has an important role in inhibiting various viruses, it consti-
tutes an excellent template for developing antiviral therapies
(Table 3), especially in cases where vaccines are not available or in-
effective. Because of the signiﬁcance of this central fragment of LL-
37, further efforts were devoted to the understanding of the mecha-
nism of action as well as functional roles of the cationic amino acids
using GF-17 as a model (below).
4. Biophysical insight into membrane permeation, disruption and
lipid domain formation by the major antimicrobial region of
human LL-37
4.1. Membrane permeation
As shown in Fig. 2A, Gram-negative bacteria possess two layers of
membranes: an outer membrane, containing LPS in the outer mono-
layer, and an inner membrane rich in PG. The total phospholipid
composition of both membranes is shown in Table 1 (see also [101]).
In general the membranes of Gram-negative bacteria are rich in phos-
phatidylethanolamine (PE) with variable amounts of the anionic lipids
PG and CL. To follow peptide-mediated membrane permeation, theLehrer group designed a dual reporter system for Gram-negative bacte-
ria using E. coliML-35p [69]. Two chromogenic reporter molecules are
used to monitor permeabilization of outer and inner membranes in a
single assay. Nitroceﬁn, a chromogenic cephalosporin, cannot cross
the outer membrane and is excluded from the periplasmic space. How-
ever, permeabilization of the outermembrane allows nitroceﬁn to enter
the periplasmwhere it is cleaved by a β-lactamase and produces a color
change that can be monitored spectrophotometrically at 486 nm. Since
this strain of E. coli lacks lactose permease, o-nitrophenylgalactose
(ONPG) cannot traverse its inner membrane to be cleaved by cytoplas-
mic β-galactosidase to o-nitrophenol, unless permeabilization of the
inner membrane occurs. ONPG cleavage produces a color change that
can be measured spectrophotometrically at 420 nm. Using this dual re-
porter system, we compared the membrane permeation ability of the
single alanine variants of the ﬁve cationic amino acids in both the GF-
17 and KR-12 peptide series. For GF-17, antimicrobial activity was re-
ducedwhen either R23 or K25wasmutated to an alanine. Interestingly,
the R23A peptide variant was unable to permeate either the outer or
inner membranes of E. coli, identifying R23 as a critical cationic side
chain formembrane permeation [21]. In contrast, the KR-12 peptide be-
camemoremembrane permeablewhen either R23 or K25wasmutated
to an alanine [59]. Correspondingly, these two KR-12 variants became
more active (lower MIC values) against E. coli. It is evident that the
membrane permeation ability of the peptide corresponds well to anti-
microbial activity for both peptides. What was puzzling was the oppo-
site effects observed in the KR-12 and GF-17 cases. Since GF-17, a
major antimicrobial peptide of LL-37 (Table 3), was sufﬁciently hydro-
phobic, the loss of R23 had a drastic effect on peptide activity [21]. In
the case of KR-12 (Fig. 3F), which corresponds to the smallest antimi-
crobial region of LL-37 (Table 3), the same substitution actually in-
creased peptide hydrophobicity, making it a more potent analog [59].
This is an important ﬁnding, showing that the peptide length deter-
mines whether peptide activity rises or decreases when a cationic
amino acid is changed to an alanine. Nevertheless, in both cases, the
critical cationic amino acids for membrane binding and permeation
are R23 and K25, which are located in the interfacial region of the am-
phipathic helices (Fig. 3). It seems that this observation applies primar-
ily to Gram-negative bacteria because there are relatively small changes
in antimicrobial activity against Gram-positive bacteria such as S. aureus
when R23 or K25 was replaced [21].
4.2. Membrane disruption: carpet or pore formation?
Membrane-targeting peptides can permeate the bacterial outer
membrane and reach the innermembrane. It is proposed that the action
of peptides onmembranes is sufﬁcient in itself to cause lethality. Exper-
imentally, membrane disruption can be viewed from TEM images and
other imaging methods. To explain membrane disruption, a variety of
models have been proposed. These include the carpet model [102],
barrel-stave [103], and toroidal pore [104]. All these models point to
the change in membrane structure in the presence of the peptides. In
many cases the pores that are formed lead to movement of ions across
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[105,106]. Such damaging effects could be lethal, leading to bacterial
death. Experimental evidence for the carpet model results when the
peptide is oriented parallel to the plane of the membrane bilayers. For
LL-37, supporting evidence for a surface location was obtained from
the lipid bilayermodel based on solid-state NMR aswell as FT-IR studies
[70,78]. These results agree with our ﬁnding from solution NMR studies
as well that suggest a surface location [54,56]. Oren and Shai have sug-
gested that LL-37 does not form a pore in a membrane [78]. However,
others have obtained evidence that LL-37 can form a pore on mem-
branes. It was suggested, based on effects of membrane curvature,
that this peptide forms a toroidal pore [74]. Itwas also suggested that al-
though LL-37 did not form a pore on its own, it did promote pore forma-
tion in cells expressing the P2X receptor [107]. Based on spectroscopic
evidence, it was suggested that either a carpet or toroidal pore mecha-
nism was possible for LL-37 [108]. Diffraction measurements, albeit at
high peptide concentrations, show a trans-bilayer orientation of the
peptide, consistent with pore formation [109]. Time-lapse ﬂuorescence
microscopy was suggested to be more consistent with a pore model
[110]. All of these results are difﬁcult to reconcile. The experimental
conditions, including the modiﬁcation of the LL-37 sequence, might
have played a role here. These observations could suggest that LL-37
adopts different states depending on the type of membrane surface.
We do not exclude the possibility that these two states represent dif-
ferent stages of peptide action onmembranes. The carpet model em-
phasizes the initial state when the peptide is coating bacterial
membranes. Subsequently, the peptide can transit to another state
and cause either membrane lysis like a detergent or pore formation
depending on the properties of the peptide, the nature of the mem-
brane, the extent of hydration, and the conditions of growth. The
curved structure of LL-37 (Fig. 3A) might be perfect for sealing the
wall of a pore or micellation of bacterial membranes like a detergent.
Another approach to understand the mechanism of action of LL-
37 is to utilize homologous primate cathelicidins. There appears to
be a balance between cationic residues contributing to peptide bind-
ing to anionic lipids and the inﬂuence of charge on peptide properties
such as aggregation. Tossi and colleagues proposed that peptides in
the free state in solution are more likely to permeate the outer mem-
brane and work on the inner membrane to kill bacteria, while those in
the aggregated form tend to stay on membrane surface and mainly act
to modulate immune functions. Being different in sequence, these
homologous cathelicidins may work via different mechanisms. For
example, atomic force microscopy (AFM) revealed a carpet-like
mode of permeabilization for RL-37 and formation of more deﬁned
worm-holes for LL-37 [111].
Although lipid vesicles may be an over-simpliﬁed model compared
to bacterial membranes, dye release from lipid vesicles may also yield
some evidence for membrane damage (pore or micellization). GF-17
can lyse lipid vesicles but not KR-12 [112]. Then, what does KR-12 do
to the membranes?
4.3. Membrane domain formation induced by LL-37 fragments
There are cases when the peptide does not pass through the
membrane and does not lyse the membrane. Under such conditions,
how could the growth of a bacterium be inhibited? There are antimi-
crobial peptides that coat bacterial surfaces [113], preventing bacte-
rial replication. The Epand laboratory has shown the formation of
lipid domains in the presence of cationic peptides or their mimicries,
providing yet an alternative model to understand peptide action
[114–120]. The fundamental force behind this can be ascribed to
the attraction of anionic lipids toward cationic peptides, leading to the
enrichment of anionic lipids around basic peptides. This peptide-
induced lipid domain formation in the membrane could have a global
impact on bacteria. For example, it would hinder bacterial signal trans-
duction that requires PG for membrane targeting of amphitropicproteins such as IIAGlc involved in E. coli glucose uptake [51,121]. It
would also inﬂuence the normal functions of other membrane-bound
proteins such as voltage-dependent potassium channels that also re-
quire proper Arg–PG interactions [122]. These effects of antimicrobial
peptides would disturb the membrane physiology of bacteria, leading
to cell growth inhibition or cell death [56]. It is relevant to mention
that human LL-37 and its variants can also induce lipid domain forma-
tion in C. albicans [123].
Multiple techniques have been used to support the mechanism of
lipid clustering. These have been recently discussed [101] and in-
clude DSC, 31P NMR, 2H NMR, freeze-fracture electron microscopy,
AFM and the combination of AFMwith polarized total internal reﬂec-
tion microscopy. KR-12 is a good model system for these experi-
ments [112,115].
Next, we have also compared the lipid clustering capability of dif-
ferent LL-37 fragments [112]. Of particular interest is the ﬁnding that
substituting 3 resides in GF-17 with the corresponding enantiomers
to produce GF-17d3 [61], resulted in a peptide with greater lipid
clustering ability. This peptide, as well as the KR-12 [56], has weaker
ability to induce liposomal leakage and to exhibit bacteriostatic ac-
tivity [124]. This may be a consequence of their lower hydrophobic-
ity, preventing them from penetrating deeply into the membrane
and perturbing it.
What types of basic amino acids are important for lipid cluster-
ing? Both GF-17 and KR-12 were utilized to answer this question. It
seems all the basic amino acids play a role, although to varying de-
grees. Therefore, the two sets of lipid-clustering basic residues are
not identical as a consequence of the change in peptide length. In
both cases, however, basic residues on the hydrophilic face appear
to be important. In addition, more ﬂexible side chains appeared to
be more important. In the case of KR-12, the basic amino acids that
are more important in lipid clustering are K18 and R29. These resi-
dues are located at the terminal regions of the peptides (Fig. 3F)
and can be more mobile than those located in the interface [59]. As
a further support for the role of ﬂexibility, the Epand laboratory
found that, among numerous antimicrobials studied up to date,
most ﬂexible peptide mimicries also showed the largest degree of
lipid clustering [106,125].
More generally, the formation of a lipid domain in the presence of
cationic peptides is related to the reconstitution of the system into a dif-
ferent phase diagram. Therefore, additional non-peptide factors such as
lipid chain length and packing density may come into play [126,127].
Membrane segmentation can generate defects and facilitate the inser-
tion of peptides into the lipid bilayers, leading to pore formation.4.4. New insights into the membrane perturbation potential model
It has been realized for a long time that both hydrophobic and basic
amino acids play an essential role in determining peptide activity
[1–4,10,78,102–105]. When a single parameter fails to correlate struc-
ture with activity, we found it useful to combine the hydrophobic and
basic elements. Wang et al. [70] derived the membrane perturbation
potential model based on a comparison of the 3D structures of a non-
toxic bacterial membrane anchor and antimicrobial and anticancer pep-
tide aurein 1.2, both containing two lysines. The bacterial membrane
anchor sequence, with a short 3-turn helix (10 residues), was able to as-
sociate with anionic PG but not phosphocholines, verifying the impor-
tant role of electrostatic interactions for preferential binding to
bacterial membranes rich in PG [121]. Although both are helical pep-
tides, the bacterial membrane anchor with a shallow hydrophobic sur-
face is unable to deeply penetrate the membrane, thereby it is not
toxic to bacteria. In contrast, aurein 1.2 has a broader hydrophobic sur-
face, enabling deeper membrane penetration to kill bacteria [70]. In-
deed, solid-state NMR studies indicate that aurein 1.2 acts via a carpet
model [71–73]. Likewise, DFTamP1, a peptide designed based on the
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kill MRSA USA300 [128].
Using peptides from the central antimicrobial region of LL-37 as
models, we have learned the following: (1) The peptide sequence
order is not important for antibacterial activity but essential for
anti-HIV activity [22,129]. (2) Peptide length (related to mainly hy-
drophobicity) is clearly important for the antimicrobial activity of
this helical peptide. While truncation of GF-17 into KR-12 reduced
antimicrobial activity [56], an extension of the helical region of the
bacterial membrane anchor by one turn made the peptide antibacte-
rial [70]. (3) The aromatic phenylalanines are involved in membrane
binding and they may show clear difference in micelle penetration
depth [129]. (4) The continuity of the hydrophobic surface of an am-
phipathic helix is important for a deep penetration into membranes
[55]. (5) Cationic amino acids of GF-17 appear to have multiple roles
such as membrane binding, permeation, and domain formation [21].
Among the ﬁve basic amino acids, interfacial R23 plays an essential
role in these membrane interactions, while cationic residues on the
hydrophilic face tend to be more important in lipid clustering. (6) It is
important that the peptide length determines whether the activity
goes up or down when an interfacial cationic arginine is replaced by
an alanine. For a more hydrophobic GF-17, the loss of R23 reduces
peptide activity, whereas the peptide antibacterial activity increased
in the case of less hydrophobic KR-12 [59]. These new results shed
additional light on the membrane perturbation potential (MPP)
model proposed earlier. The hydrophobic surface bordered by the in-
terfacial basic residues deﬁnes the ﬁrst action layer important for
membrane binding, membrane permeation, and peptide activity,
while non-interfacial basic amino acids on the hydrophilic surface
could modulate other physical processes such as membrane domain
formation. With the accumulation of data, it may become feasible to
quantify the MPP as a measure of peptide membrane perturbation
ability. This will form the basis for us to rationally design peptides
with desired MPP.
There are also some antimicrobial peptides, however, with non-
helical structures. For example, Pro-rich peptides and Trp-rich
lactoferrins do not adopt a regular helical structure. In the case of a
15mer lactoferrin fragment, membrane interactions did not correlate
with antimicrobial activity [130–132]. Likewise, alanine substitutions
of lysines or the arginine of PAF26 (Ac-RKKWFW-NH2) showed no ef-
fect on antifungal activity against plant pathogen Penicillium digitatum,
although substitution of hydrophobic residues did [131]. It is notable
that these peptides are proposed to cross cellular membranes and
bind to internal targets. Such peptides, therefore, do not ﬁt into the
MPP model we highlighted above for membrane-targeting helical
peptides. Interestingly, both helical and non-helical peptides could
contain numerous aromatic residues in the sequence. While LL-37
contains four phenylalanines, PAF26 contains two Trp residues. The ar-
omatic residues are known to prefer membrane interfaces [133–136].
Aromatic amino acids such as phenylalanines can also form the inter-
face for protein–protein interactions [56].
5. Concluding remarks
Human cathelicidin LL-37 has been demonstrated to have antimi-
crobial activity against a variety of microbial pathogens, including
bacteria, fungi, viruses, and parasites. It appears that LL-37 targets
bacterial membranes (Fig. 2). The high-quality 3D structure of
human LL-37 determined by 3D NMR spectroscopy (Fig. 3) reveals
that it uses a long amphipathic helix (residues 1–31) to interact with
the outer and inner membranes of Gram-negative bacteria, and the
C-terminal tail (residues 32–37) is not required for membrane bind-
ing (Fig. 3A). The two hydrophobic domains of LL-37 are critical for
binding LPS and explain its anti-septic effects. It is also established
that both hydrophobic aromatic phenylalanines and interfacial cat-
ionic lysines and arginines of LL-37 participate in membrane binding(Fig. 4B). This amphipathic structure provides a solid basis for a
membrane surface location at the equilibrated experimental condi-
tions and may represent the initial state during bacterial killing.
While acidic residues of LL-37 appear to control peptide aggregation
as well as activity [137], our work also sheds light on possible roles of
cationic amino acids in LL-37 fragments. In particular, the central
cationic R23 in the central helix of LL-37 can directly interact with
anionic PG (Fig. 4B) [54,56], consistent with its critical roles in mem-
brane targeting and permeation.
It is pertinent to point out that, while bacterial membrane disrup-
tion is emphasized as the major mechanism of action of LL-37 in sev-
eral studies [56,61,74,78,126,127], we do not exclude contributions
from an alternative mechanism. It is demonstrated that the major an-
timicrobial region of LL-37 can directly associate with DNA based on
gel shift assays (T. Lushinikova and G. Wang, unpublished). Once bac-
terial membranes have been damaged due to the action of LL-37, DNA
binding could also occur in the same manner as observed for DNA-
binding dyes [21]. R23 is proposed to be essential for DNA binding
as well [138]. It is believed that binding of LL-37 to DNA or other neg-
ative components is responsible for the loss of antimicrobial activity
in a cystic ﬁbrosis (CF) lung [139]. In both cases, the binding of LL-
37 to DNA may generate a new signal for the biological system. The
LL-37/DNA complex may trigger part of the immune modulation in
analogy to the neutralization of LPS by the same peptide. LL-37 may
deliver DNA into host cells to be recognized by TLR-9 [140,141].
There are also other pathways for immune modulation. LL-37 can di-
rectly associate with host cell receptors such as formyl peptide
receptor-like 1 (FPRL1) and P2X7 [142,143]. Elucidation of these
novel mechanisms may hold the key to new strategies for treating
infectious diseases.
There have been attempts to map the functions of LL-37 to deﬁned
peptide regions. It appears the N-terminal region of LL-37 is not im-
portant for antibacterial activity since the N-terminal fragment LL-23
showed activity only to susceptible bacterial strains [55]. However,
LL-23 may have immune modulation roles. In particular, a change
of S9 of LL-23 to A9 or V9 led to distinct chemokine release patterns.
NMR studies revealed that both the N-terminal and C-terminal re-
gions of LL-37 are involved in peptide aggregation [56]. This explains
the fact that truncation of either the N-terminal or C-terminal 6–7
residues of LL-37 could increase peptide potency. It is clear now
that the central helix of LL-37 is of primary importance in inhibiting
microbes (Fig. 4A). A variety of fragments have been derived based
on this central region (Table 3). GF-17, a peptide corresponding to
the major antimicrobial region of human LL-37, is known to have ac-
tivity against pathogenic superbugs such as MRSA and HIV-1, as well
as cancer [21,22,61]. The minimal peptide sequence may vary de-
pending on the type of antimicrobial activity (Table 3). KR-12 is suf-
ﬁcient to inhibit E. coli, whereas FK-13, the LL-37 core peptide, is the
minimal sequence for inhibiting HIV-1 [22,56]. Furthermore, GF-17
is potent against MRSA USA300 [21]. However, an even longer frag-
ment, RK-25, is suggested for the anti-bioﬁlm activity against
P. aeruginosa [87]. Therefore, there is a consensus that the central
fragment of LL-37 is required for antibacterial, anti-bioﬁlm, antiviral
activities. Table 3 contains a collection of interesting LL-37 templates
for developing novel therapeutic molecules for treating different in-
fectious diseases. Alternatively, elucidation of other inducing factors
and the mechanism of induction of LL-37 could offer a new avenue
for treating infectious diseases [144].Acknowledgements
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